Aeon Biopharma Inc (AEON)
$0.77
Performance
- $0.75$0.84$0.77
2.78%
Downside
Day's Volatility :10.83%
Upside
8.28%
- $0.71$17.17$0.77
8.23%
Downside
52 Weeks Volatility :95.88%
Upside
95.52%
Returns
| Period | Aeon Biopharma Inc | Index (Russel 2000) |
|---|---|---|
3 Months | -54.23% | 0.0% |
6 Months | -93.7% | 0.0% |
1 Year | -84.37% | 0.0% |
3 Years | -92.07% | -22.3% |
Highlights
Market Capitalization | 32.8M |
Book Value | - $0.71 |
Earnings Per Share (EPS) | -0.17 |
Wall Street Target Price | 5.0 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -597.69% |
Return On Equity TTM | 0.0% |
Revenue TTM | 0.0 |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | 0.0 |
EBITDA | -43.9M |
Diluted Eps TTM | -0.17 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | 0.72 |
EPS Estimate Next Year | -0.69 |
EPS Estimate Current Quarter | -0.19 |
EPS Estimate Next Quarter | -0.22 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 549.35%
Technicals Summary
Sell
Neutral
Buy
Aeon Biopharma Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Aeon Biopharma Inc | -21.9% | -93.7% | -84.37% | -92.07% | -92.03% |
 Regeneron Pharmaceuticals, Inc. | 5.97% | 16.25% | 37.11% | 69.18% | 305.56% |
 Novo Nordisk A/s | 9.99% | -3.52% | 34.24% | 158.74% | 417.73% |
 Alnylam Pharmaceuticals, Inc. | -5.15% | 64.67% | 22.72% | 31.08% | 198.44% |
 Vertex Pharmaceuticals Incorporated | 0.45% | 14.0% | 36.06% | 143.5% | 167.72% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Aeon Biopharma Inc | NA | NA | NA | 0.72 | 0.0 | -5.98 | NA | -0.71 |
Regeneron Pharmaceuticals, Inc. | 29.93 | 29.93 | 1.54 | 45.05 | 0.17 | 0.08 | NA | 261.41 |
Novo Nordisk A/s | 44.01 | 44.01 | 1.98 | 3.44 | 0.89 | 0.23 | 0.01 | 25.24 |
Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -2.55 | -15.01 | 0.02 | NA | -0.02 |
Vertex Pharmaceuticals Incorporated | 32.84 | NA | 0.57 | 0.32 | -0.03 | 0.13 | NA | 57.26 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Aeon Biopharma Inc | Buy | $32.8M | -92.03% | NA | 0.0% |
Regeneron Pharmaceuticals, Inc. | Buy | $124.7B | 305.56% | 29.93 | 32.04% |
Novo Nordisk A/s | Buy | $585.3B | 417.73% | 44.01 | 34.84% |
Alnylam Pharmaceuticals, Inc. | Buy | $32.3B | 198.44% | NA | -3.11% |
Vertex Pharmaceuticals Incorporated | Buy | $120.9B | 167.72% | 32.84 | -4.74% |
Insights on Aeon Biopharma Inc
Vs REGN
In the last 1 year, Regeneron Pharmaceuticals, Inc. has given 37.1% return, outperforming this stock by 121.5%
Vs NVO
In the last 3 years, Novo Nordisk A/s has given 69.2% return, outperforming this stock by 161.3%
Company Information
we are a nasdaq-listed special purpose acquisition company whose business purpose is to effect a merger or similar business combination with one or more businesses. our acquisition strategy is to identify and complete our initial business combination with a medical technology company in the healthcare industry. our sponsor team consists of chairman/ceo robert palmisano, president vikram malik, cfo oleg grodnensky and chief legal officer david meredith.
Organization | Aeon Biopharma Inc |
Employees | 5 |
CEO | Mr. Marc Forth |
Industry | Miscellaneous |
Discover More
A Spac I Acquisition Corp
$0.77
-5.92%
Keyarch Acquisition Corp
$0.77
-5.92%
Connexa Sports Technologies Inc
$0.77
-5.92%
Us Value Etf
$0.77
-5.92%
First Wave Biopharma Inc
$0.77
-5.92%
Global X Msci Next Emerging
$0.77
-5.92%
Fat Projects Acquisition Corp
$0.77
-5.92%
Capital Link Global Fintech
$0.77
-5.92%
Applied Uv Inc
$0.77
-5.92%